中文
Products

hs-cTnI Detection Kit

hs-cTnI Detection Kit (Quantum Dots-Based Immunofluorescence Chromatography)

Intended Use

For the in vitro quantitative detection of High-sensitivity cardiac Troponin I (hs-cTnI) in serum, plasma, or whole blood.

hs-cTnI Detection Kit

Clinical Department

Clinical Laboratory, Ambulance/Emergency Department/ICU/Catheterization Laboratory, Cardiology Department/CCU/Thoracic Surgery Department, Respiratory Medicine Department, Geriatrics Department, Physical Examination Center, etc.

Product Parameters Clinical application

[Product Name]hs-cTnI Detection Kit

[Sample Type]Serum, plasma, and whole blood

[Intended Use]

For the in vitro quantitative detection of High-sensitivity cardiac Troponin I (hs-cTnI) in serum, plasma, or whole blood.

[Clinical Department]

Clinical Laboratory, Ambulance/Emergency Department/ICU/Catheterization Laboratory, Cardiology Department/CCU/Thoracic Surgery Department, Respiratory Medicine Department, Geriatrics Department, Physical Examination Center, etc.

Product Parameters

Item

hs-cTnI

Test Time

13min

Sample Type

Serum, plasma, and whole blood

Sensitivity

0.005ng/mL

Storage Condition

4-30℃

Packing Specification

Card Type: 25 Tests/Kit, 50 Tests/Kit

Cartridge type: 25 Tests/Kit, 50 Tests/Kit

1. "Gold Standard" for the Diagnosis of Acute Myocardial Infarction (AMI): Recommended by the European Society of Cardiology (ESC) and the American College of Cardiology (ACC) as the primary indicator for assisting in the diagnosis of acute myocardial infarction (AMI).

2. Early Differentiation of Etiologies for Acute Chest Pain: High-sensitivity cardiac troponin I (hs-cTnI) enables earlier diagnosis or exclusion of myocardial infarction (MI) compared with conventional cTnI:

① Advances the diagnosis of AMI patients by 1–2 hours;

② Rules out the possibility of AMI 2 hours earlier than previously possible.

3. Higher Sensitivity of hs-cTnI for Risk Stratification of Cardiovascular Events: Elevated hs-cTnI levels are significantly associated with subsequent cardiovascular events. It is an important basis for confirming the diagnosis and risk stratification of non-ST-segment elevation acute coronary syndrome (NSTE-ACS), with higher sensitivity and specificity compared with traditional cardiac biomarkers.

4. Minor Myocardial Injury.


微信公众平台

官网二维码